Table 8 Transaminase elevation relations with the patients’ characteristics among Rosuvastatin users (N = 323)

Gender

Male (N = 203)

28(13.8%)

175(86.2%)

1.040

(0.5425 to 2.027)

0.9999

Female (N = 120)

16(13.3%)

104(86.7%)

Age

21–55 (N = 205)

31(15%)

174 (85%)

1.439

(0.7255 to 2.975)

0.3186

56–82 (N = 118)

13(11%)

105(89%)

Body mass index

(BMI)

> 30 (N = 123)

19(15.5%)

104 (84.5%)

1.279

(0.6833 to 2.427)

0.5051

< 30 (N = 200)

25(12.5%)

175(87.5%)

Ethnicity

Arabs

(N = 143)

13(9%)

130 (91%)

2.081

(1.054 to 4.279)

0.0353

Non- Arabs

(N = 180)

31(17.3%)

149(82.7%)

Smoking

Smokers

(N = 79)

15(19%)

64(81%)

1.808

(0.9203 to 3.636)

0.1256

Non-smokers

(N = 244)

28(11.5%)

216(88.5%)

Alcohol Use

Yes

(55)

12 (21.8%)

43(78.2%)

2.058

(0.9902 to 4.222)

0.0812

No

(268)

32(11.9%)

236(88.1%)

Combination therapy

Ezetimibe

(N = 123)

23(18.7%)

100(81.3%)

1.960

(1.024 to 3.711)

0.0449

No Ezetimibe

(N = 200)

21(10.5%)

179(89.5%)

Rosuvastatin dose

Moderate intensity (5 or 10 mg

(N = 186)

29(15.6%)

157(84.4%)

1.502

(0.7804 to 2.850)

0.2539

High intensity

(20 or 40 mg) (N = 137)

15(11%)

122(89%)

SLCO1B1 rs4149056 (521T > C)

Carriers

(N = 77)

13(16.8%)

64(83.2%)

1.409

(0.6981 to 2.880)

0.3447

Non-carriers

(N = 246)

31(12.6%)

215(87.4%)

ABCG2 rs2231142 (421 C > A)

Carriers

(N = 69)

19(27.5%)

50(72.5%)

3.481

(1.771 to 6.574)

0.0005

Non-carriers

(N = 254)

25(9.8%)

229(90.2%)